Imbruvica (ibrutinib)

GLOW study: Frail CLL patients treated with ibrutinib+venetoclax have a better PFS regardless of MRD status than patients receiving chlorambucil+obinutuzumab. Ibrutinib + venetoclax should be the preferred regimen for this patient population @JCO_ASCO https://t.co/slXTGVy0ZX (@SLentzsch)

Seymour et al @BloodJournal Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR https://t.co/nfEj9EAsjI #CLLsm (@chanyooncheah)

The utility of an endpoint (and its surrogacy or otherwise) is not only disease-specific, but also, as @DrJFriedberg highlights, therapy-specific That lesson was also important for ibrutinib’s initial approval in CLL (lymphocytosis) (@Eddie_Cliff)

Young male patient with mantle cell lymphoma del17p+, tp53 mut not detected, refractory to R-DHAP, now on R-ibrutinib. Would you go for allo in Cr1? No pirto or cart available in 🇦🇷 in case of relapse. @tobyeyre82 @michaelwangmd (@laura_korin)

ELEVATE-RR showed acala safer and same PFS vs ibrutinib in relapsed CLL ALPINE showed zanu safer and improved PFS compared to ibrutinib in relapsed CLL. No data for acala vs zanu. Given safety, and extrapolating from R/R CLL, acala/zanu preferred for frontline as well (@NitinJainMD)

65/♂️/ newly diagnosed CLL, needs treatment. IGHv unmutated and del17p. ECOG 1. No co-morbidities !! What's your treatment of choice?? •Ven-G •Ven-Ibrutinib •Acalabrutinib •Something else #MedTwitter @NicoGagelmann @Eddie_Cliff @matthew_mei (@nihardesai7)

Ibrutinib Rituximab vs Rituximab, no better CR but better marginally PFS in frontline follicular #lymsm #17icml https://t.co/iACgf78kyf (@HayderSaeed_MD)

Rituximab and Ibrutinib in frontline MZL #lymsm showing a ORR 91% and 2 yr PFS 77% #17icml https://t.co/DmB1fnQdn7 (@HayderSaeed_MD)

SELENE RCT of ibrutinib vs placebo + RCHOP or BR in R/R FL or MZL #17ICML: - 403 pts randomized, vast majority FL, most got BR - no difference in PFS or OS (same for small MZL subgroup) - more high grade AEs in ibr arm Not surprising, but 7 yrs of f/u is great. #lymsm (@majorajay)

Pleased to share @fredhutch results of #venetoclax and #ibrutinib in relapsed follicular lymphoma at #17ICML. #Zanubrutinib Rosewood study update also supports use of #BTK inhibitor in FL. @Rcl14L @mshadman @KatieLaiMD_MPH @DunleavyKieron #lymsm #17ICML (@UjjaniC)

Dr Thieblemont presents IELSG47/MALIBU study of ibrutinib and rituximab in MZL. Excellent ORR and encouraging CR rates in both subtypes but shorter PFS in NMZL #17ICML #lymSM @LysaLymphoma (@chanyooncheah)

Rituximab-Ibrutinib in 1L for splenic and nodal MZLs (IELSG47/MALIBU Phase Il) #17ICML, by Dr C Thieblemont Higher CR rate in nodal cases but shorter PFS when compared with splenic 🤔 (@Fer_martinmoro)

@c_thieblemont Rituximab+ibrutinib in untreated splenic and nodal MZL. Ibrutinib 2 y, 8 doses of R. n=30+15. CR 12 mo: 53%. PFS at 5 y: 86% and 59%. Splenic better DOR. Safe and effective. #17ICML (@Dr_Daniel_Molin)

1. At the time of trial initiation, CLB-Obi was standard 1L therapy for unfit #CLL patients. 2. 70% of pts received targeted agents as 2L therapy in control arm. 2. Ven-Obi outperformed FCR, Ven-R in the #CLL13 trial, and was equivalent to Ven-Obi-ibrutinib triplet. (@HallekMichael)

Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features @Prasshmehta @DrPMPGI @IndianYoungOnco https://t.co/AR0XDDJYaW (@DeLionofPunjab)

Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features @Prasshmehta @DrPMPGI @IndianYoungOnco https://t.co/AR0XDDJqlo (@DeLionofPunjab)

I have treated a couple pts w afib related to ibrutinib. Makes anticoagulation a big issue given underlying hematologic abnormalities. Personally would not take it if I had asx CLL. (@CardioNP)

10-yr CLL12 follow-up results #17ICML - 363 pts with asympt CLL at increased risk randomized to placebo vs ibrutinib - ibr arm with improved EFS/PFS/TTNT - no diff in OS! - much more cardiotox in ibr arm Impressive study in the BTK era that supports watch & wait. #lymsm (@majorajay)

This should have been plenary and highlights the major bias against neg data, which can be equally practice informing! @icmlugano #17ICML #lymsm CLL12 Ibrutinib vs placebo in asympt CLL -⬆️ PFS benefit but NO OS benefit -Even placebo arm had 99% AEs So many lessons learnt! (@PallawiTorkaMD)

Patients who respond to ibrutinib lead-in more likely to do well to TEDD(I)-R for secondary CNSL. CD10 negativity may be a marker for ibrutinib sensitivity. #17ICML (@DrLizBrem)

CONGRESS|#17ICML @michaelwangmd, @MDAndersonNews summarizes the phase II WINDOW-2 trial results on chemo-free induction with ibrutinib-rituximab-venetoclax (IRV) followed by R-hyperCVAD/MTX in young pts with untreated MCL. IRV induced deep responses and was safe #lymsm #lymphoma (@lymphomahub)

First at #17ICML mantle cell session: ICML-2015 study of MRD-adapted rituximab + ibrutinib in indolent MCL. - 50 pts (15% TP53mut) - ORR 84% (CR 82%, MRD- 80%) - mDOR 67 mo, mPFS >6 years - 26% discontinuation d/t AEs Doesn't change W&W; TP53 still with poor prognosis #lymsm (@majorajay)

Congrats to Dr Eva Giné @hematoclinicbcn for her oral presentation at #17ICML! 👏👏👏 Five-year update of the first-line IMCL-2015 @geltamo study. Prolonged molecular and clinical responses were observed after MRD-driven ibrutinib discontinuation (📑 abstract #98) (@Fer_martinmoro)

Great data from #17ICML that lymphoma docs can use to counsel about zanu vs ibrutinib. Regardless of the BTK inhibitor, there is improvement in overall QOL and physical/role function, as well as ongoing improvement in fatigue, pain, and diarrhea up to 1 year. #lymsm #leusm (@majorajay)

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL: no OS benefit and wait and see still preferred (@MinnemaMonique)

#EHA2023 #CLL Zanubrutinib decreases both CD8+ and CD4+ cells in line what previously observed in ibrutinib treated patients P609 (@gellc)

Older and frail CLL patients treated with ibrutinib + venetoclax have a better PFS regardless of the MRD status than patients receiving chlorambucil + obinutuzumab. Ibrutinib + venetoclax should be the preferred regimen for this patient population @JCO_ASCO #CLL (@SLentzsch)

An N of 1 study using organoid based screening data (via @SEngineMedicine) Extraordinary clinical response to ibrutinib in low-grade #ovariancancer guided by organoid drug testing https://t.co/W1d2KSntyH @BarbaraAGoff @SwisherLiz (@Aiims1742)

Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZL @MayoClinic #lymsm #hematology https://t.co/FtHtlZznHN (@OncLive)

Long term fup of the OASIS I trial at #EHA2023 Ibrutinib plus venetoclax + Anti-CD20 in 1L and R/R #MCL 4Y PFS 50% in R/R Cohort 4Y PFS 80% in 1L Cohort v promising combination Ongoing @NCRI_partners + @LysaLymphoma group OASIS II testing Ibr-R vs Ibr-Ven-R in 1L MCL #lymsm (@tobyeyre82)

UK NHSE Covid19 scheme Largest 1L series of BTKi in MCL to date #Ibrutinib +/-R in 1L #MCL high risk (HR) ≥1 TP53 mut/del, blastoid/pleomorph or Ki67%/MiB1 ≥30% N=149 35% HR mPFS for all 26m mPFS HR PFS 9.7m Work to do in high risk 1L MCL cBTKi+CD20 enough? #EHA2023 #lymsm (@tobyeyre82)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial https://t.co/OCxfPdqpXe #lymsm (@smbenlazar)

👏👏👏Promising results from the GAIA CLL13 trial shedding light on time-limited therapy in young fit #CLL patients Venetoclax–Obinutuzumab and Venetoclax–Obinutuzumab–Ibrutinib regimens exceed CIT while Rituximab-Venetoclax falls behind. (@Rocustidiano)

Thank you @jeff_sharman. One of the next trials, #CLL17, which has finished recruitment, will hopefully give some answers, as it compares Venetoclax (Ven)-Ibrutinib to Ven-Obinutuzumab and continued Ibrutinib monotherapy. (@HallekMichael)

Important note: trial only included patients with TP53-wild-type CLL. Unclear how much ibrutinib really adds from this study. #lymsm (@majorajay)

Venetoclax–obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy as first-line treatment in fit patients with CLL-GAIA–CLL13 https://t.co/VdiT4whyTZ (@drkpavithran)

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL https://t.co/zYSG2unuyW #leusm (@smbenlazar)

Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax https://t.co/SqJMV0NMFw (@smbenlazar)

66,♂️, no co-morbidities, living w/ CLL for 12 yrs now 4 yrs w/w 5 yrs of ibrutinib 3 yrs Ven+R Now del17p+ IGHv status not known CD38 expression⤴️ No pirtobrutinib available Acalabrutinib generic but don't know if C481 mutated🤷‍♂️ Options ? @NitinJainMD @BijoyTelivala (@nihardesai7)

BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib https://t.co/zIMIU2Waoa (@tobyeyre82)

New #JITC article: Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma https://t.co/OkuWBuwrwF @lawfong @AACRPres @coussens_lisa (@jitcancer)

Brown @DanaFarber shows superiority in PFS and safety for Zanubrutinib over ibrutinib in R/R BTKi naive CLL. Benefit in TP53 mutated disease, less AF and serious cardiac events. #CLLsm #ASH22 late breaking session (@chanyooncheah)